Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Apr;40(4):914–919. doi: 10.1128/aac.40.4.914

Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

S Gassis 1, P K Rathod 1
PMCID: PMC163230  PMID: 8849251

Abstract

A combination of 5-fluoroorotate and atovaquone eliminated Plasmodium falciparum in long-term cultures more efficiently than either compound alone. The improved potency came not through synergistic activity but through decreased frequency of drug resistance. In support of this finding, it was shown that 5-fluoroorotate and atovaquone do not act in a synergistic fashion, that 5-fluoroorotate-resistant and atovaquone-resistant P. falciparum organisms generated in vitro do not show cross-resistance, and that the frequency of simultaneous resistance to the two compounds approached the product of their individual resistance frequencies. To demonstrate the last finding, and establish proof of principle, an in vitro method was developed for measuring the frequency of drug resistance in P. falciparum. By this method, it was shown that the frequency of resistance to 10(-7) M 5-fluoroorotate was about 10(-6) and the frequency of resistance to 10(-8) M atovaquone was about 10(-5); the frequency of simultaneous resistance to a combination of 10(-7) M 5-fluoroorotate and 10(-8) M atovaquone was less than 5 x 10(-10). On the basis of additional measurements, it was estimated that the frequency of simultaneous resistance to higher, pharmacologically more relevant, concentrations of 10(-6) M 5-fluoroorotate and 10(-7) M atovaquone would be less than 10(-17). Control experiments demonstrated that these drug combinations did not cause increased toxicity to mammalian cells in culture. On this basis, it is predicted that a combination of 5-fluoroorotate and atovaquone will successfully eliminate typical malarial infections in animals and in human patients at doses that are readily tolerated.

Full Text

The Full Text of this article is available as a PDF (230.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blanchard T. J., Mabey D. C., Hunt-Cooke A., Edwards G., Hutchinson D. B., Benjamin S., Chiodini P. L. Multiresistant falciparum malaria cured using atovaquone and proguanil. Trans R Soc Trop Med Hyg. 1994 Nov-Dec;88(6):693–693. doi: 10.1016/0035-9203(94)90233-x. [DOI] [PubMed] [Google Scholar]
  2. Bunnag D., Malikul S., Chittamas S., Chindanond D., Harinasuta T., Fernex M., Mittelholzer M. L., Kristiansen S., Sturchler D. Fansimef for prophylaxis of malaria: a double-blind randomized placebo controlled trial. Southeast Asian J Trop Med Public Health. 1992 Dec;23(4):777–782. [PubMed] [Google Scholar]
  3. Canfield C. J., Pudney M., Gutteridge W. E. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol. 1995 May;80(3):373–381. doi: 10.1006/expr.1995.1049. [DOI] [PubMed] [Google Scholar]
  4. Desjardins R. E., Canfield C. J., Haynes J. D., Chulay J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979 Dec;16(6):710–718. doi: 10.1128/aac.16.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fry M., Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol. 1992 Apr 1;43(7):1545–1553. doi: 10.1016/0006-2952(92)90213-3. [DOI] [PubMed] [Google Scholar]
  6. Gómez Z. M., Rathod P. K. Antimalarial activity of a combination of 5-fluoroorotate and uridine in mice. Antimicrob Agents Chemother. 1990 Jul;34(7):1371–1375. doi: 10.1128/aac.34.7.1371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hammond D. J., Burchell J. R., Pudney M. Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol. 1985 Jan;14(1):97–109. doi: 10.1016/0166-6851(85)90109-4. [DOI] [PubMed] [Google Scholar]
  8. Haynes J. D., Diggs C. L., Hines F. A., Desjardins R. E. Culture of human malaria parasites Plasmodium falciparum. Nature. 1976 Oct 28;263(5580):767–769. doi: 10.1038/263767a0. [DOI] [PubMed] [Google Scholar]
  9. Hudson A. T. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol Today. 1993 Feb;9(2):66–68. doi: 10.1016/0169-4758(93)90040-m. [DOI] [PubMed] [Google Scholar]
  10. Hudson A. T., Dickins M., Ginger C. D., Gutteridge W. E., Holdich T., Hutchinson D. B., Pudney M., Randall A. W., Latter V. S. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res. 1991;17(9):427–435. [PubMed] [Google Scholar]
  11. Hudson A. T., Randall A. W., Fry M., Ginger C. D., Hill B., Latter V. S., McHardy N., Williams R. B. Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity. Parasitology. 1985 Feb;90(Pt 1):45–55. doi: 10.1017/s0031182000049003. [DOI] [PubMed] [Google Scholar]
  12. Ittarat I., Asawamahasakda W., Meshnick S. R. The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp Parasitol. 1994 Aug;79(1):50–56. doi: 10.1006/expr.1994.1058. [DOI] [PubMed] [Google Scholar]
  13. Looareesuwan S., Wilairatana P., Vanijanonta S., Kyle D., Webster K. Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet. 1992 Feb 8;339(8789):369–369. doi: 10.1016/0140-6736(92)91690-a. [DOI] [PubMed] [Google Scholar]
  14. Oduola A. M., Weatherly N. F., Bowdre J. H., Desjardins R. E. Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro. Exp Parasitol. 1988 Jun;66(1):86–95. doi: 10.1016/0014-4894(88)90053-7. [DOI] [PubMed] [Google Scholar]
  15. Peters W. The prevention of antimalarial drug resistance. Pharmacol Ther. 1990;47(3):499–508. doi: 10.1016/0163-7258(90)90067-c. [DOI] [PubMed] [Google Scholar]
  16. Pfefferkorn E. R., Borotz S. E., Nothnagel R. F. Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate. J Parasitol. 1993 Aug;79(4):559–564. [PubMed] [Google Scholar]
  17. Rathod P. K., Gomez Z. M. Plasmodium yoelii: oral delivery of 5-fluoroorotate to treat malaria in mice. Exp Parasitol. 1991 Nov;73(4):512–514. doi: 10.1016/0014-4894(91)90075-8. [DOI] [PubMed] [Google Scholar]
  18. Rathod P. K., Khatri A., Hubbert T., Milhous W. K. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1989 Jul;33(7):1090–1094. doi: 10.1128/aac.33.7.1090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rathod P. K., Khosla M., Gassis S., Young R. D., Lutz C. Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 1994 Dec;38(12):2871–2876. doi: 10.1128/aac.38.12.2871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rathod P. K., Leffers N. P., Young R. D. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrob Agents Chemother. 1992 Apr;36(4):704–711. doi: 10.1128/aac.36.4.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rathod P. K., Reshmi S. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase. Antimicrob Agents Chemother. 1994 Mar;38(3):476–480. doi: 10.1128/aac.38.3.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Salako L. A., Adio R. A., Walker O., Sowunmi A., Stürchler D., Mittelholzer M. L., Reber-Liske R., Dickschat U. Mefloquine-sulphadoxine-pyrimethamine (Fansimef, Roche) in the prophylaxis of Plasmodium falciparum malaria: a double-blind, comparative, placebo-controlled study. Ann Trop Med Parasitol. 1992 Dec;86(6):575–581. doi: 10.1080/00034983.1992.11812712. [DOI] [PubMed] [Google Scholar]
  23. Seymour K. K., Lyons S. D., Phillips L., Rieckmann K. H., Christopherson R. I. Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry. 1994 May 3;33(17):5268–5274. doi: 10.1021/bi00183a033. [DOI] [PubMed] [Google Scholar]
  24. Trager W., Jensen J. B. Human malaria parasites in continuous culture. Science. 1976 Aug 20;193(4254):673–675. doi: 10.1126/science.781840. [DOI] [PubMed] [Google Scholar]
  25. Wu Y., Sifri C. D., Lei H. H., Su X. Z., Wellems T. E. Transfection of Plasmodium falciparum within human red blood cells. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):973–977. doi: 10.1073/pnas.92.4.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Young R. D., Rathod P. K. Clonal viability measurements on Plasmodium falciparum to assess in vitro schizonticidal activity of leupeptin, chloroquine, and 5-fluoroorotate. Antimicrob Agents Chemother. 1993 May;37(5):1102–1107. doi: 10.1128/aac.37.5.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES